dose-intensive chemotherapy compared with less intensive 'conventional' chemotherapy in a variety of solid tumors, including breast cancer, lymphoma, ovarian cancer, and Fifteen children 4 years of age or under (8-46 months), weight 7.8 to 17 kg, underwent 44 peripheral blood stem sarcomas.
hematopoiesis. [6] [7] [8] The major advantage of using PBSCs over bone marrow is the rapid hematopoietic reconstitution MNC/kg). One heavily pretreated patient experienced delayed hematologic reconstitution, while the remaining through maturation of more committed progenitor cells.
9
Early hematological recovery results in shorter duration of seven patients had a median ANC recovery to Ͼ0.5 ؋ 10 3 /l by day ؉10 (9-11 days) and platelets antibiotic use, fewer blood product transfusions, early hospital discharge, and significant cost saving. In addition, the Ͼ50 ؋ 10 3 /l by day ؉15 (12-17 days). Seven patients received PBSCs following repetitive submyeloablative collection process for PBSCs is less invasive than bone marrow harvest. PBSC collection is also a preferred source chemotherapy (ICE: ifosfamide 1.8 g/m 2 /day, etoposide 100 mg/m 2 /day ؋ 5, carboplatin 400 mg/m 2 /day ؋ 2) or of stem cells in patients who have had prior pelvic irradiation.
10
other similar combination chemotherapy. Median days to recover ANC у1 ؋ 10 3 /l and platelets у100 ؋ The safety and efficacy of PBSC collection is well established in adults and older children.
11 However, experience 10 3 /l in children receiving ICE ؉ PBSCs were 10 and 14 days, respectively, compared with 16 and 22 days in regarding the feasibility, safety, and efficacy of the procedure in infants and young children is still limited.
12-17
children receiving ICE ؉ G-CSF in historical controls.
In conclusion, collection and use of PBSCs to support We report our experience in collection and use of PBSCs in young children with refractory solid tumors to support either myeloablative chemotherapy or multicycle submyeloablative chemotherapy is well tolerated and may myeloablative chemotherapy and multicycle submyeloablative therapy. enhance hematological recovery in young children and infants. Keywords: peripheral blood stem cell collection; hematological recovery; infant Methods
PBSC mobilization
Intensification of chemotherapy is a strategy frequently Patients of Children's Hospital of Orange County who were used in treating recurrent or refractory malignancies. 1 identified as candidates for high-dose chemotherapy (either Improved clinical outcomes have been demonstrated using myeloablative or submyeloablative) for the treatment of their malignancies were eligible for PBSC collection. /kg of CD34 + blood counts and electrolytes were checked before and after cells were given following submyeloablative chemothe procedure. Patients received packed red blood cells or therapy. Patients also received hematopoietic growth facplatelet transfusions prior to leukapheresis if the hematocrit tors (rhG-CSF or rhGM-CSF) following PBSC infusion was less than 26% or platelet count less than 50 000/l to until stable myeloid recovery was achieved (usually when ensure the safety of the procedure.
absolute neutrophil count (ANC) у5000/l). CBCs were After stem cell collection, the apheresis product was cenmonitored daily following myeloablative chemotherapy and trifuged at 1500 r.p.m. for 15 min to remove the plasma three times a week after submyeloablative chemotherapy and then resuspended with 5A McCoy's modified media until ANC recovered to greater than 1000/l and platelet (Ca ++ , Mg ++ free) (Sigma, St Louis, MO, USA) supcount greater than 50 000/l. plemented with 10% autologous platelet-poor plasma to make the final cell concentration of 1-1.5 × 10 8 cells/ml. One aliquot of cell suspension was collected to check for Results mononuclear cell count and CD34
+ cell count. Cryoprotectant (DMSO 10% V/V; Tera Pharmaceuticals, Buena Park, Patient characteristics CA, USA) was then added and the final product was transferred into freezing bags and cryopreserved in a controlledFifteen children, nine boys and six girls, ages ranging from 8 months to 46 months (median 30 months), weight 7.8 kg rate freezer and stored at vapor phase in a liquid nitrogen freezer. CD34
+ cell determination was performed by flow to 17 kg with a median of 12.9 kg, underwent a total of 44 PBSC collections (Table 1) . Disease categories included cytometry using phycoerythrin (PE)-conjugated CD34 antibody and fluorescein-isothiocyanate (FITC)-conjugated neuroblastoma (five patients), PNET (three patients), medulloblastoma (two patients), malignant glioma CD45 antibody (Becton Dickinson, San Jose, CA, USA). Total nucleated cells were gated using a CD45 marker and (two patients), recurrent Wilms' tumor (two patients), and choroid plexus carcinoma (one patient). The interval the CD34 percentage was then calculated. between diagnosis and PBSC collection was 2 months in 10 unsupported platelet count у50 000/l on day 201 after PBSC infusion); the remaining seven patients had ANC patients, 4-8 months in the other four patients. One patient (patient No. 8) had abdominal radiation prior to PBSC harrecovery to greater than 500/l in 9-11 days (median 10 days) following stem cell infusion. Unsupported platelet vest; the remaining 14 patients did not receive any radiation therapy prior to PBSC harvest. counts equal to or greater than 50 × 10 3 /l occurred on day 12 to day 18 with a median of 15 days ( Table 2 ). The rate of platelet recovery did not correlate with the number of Peripheral blood stem cell collection mononuclear cell or CD34 cells from bone marrow or PBSCs infused. The median discharge date was 27 days PBSC collections were started when patients showed evidence of hematologic recovery from myelosuppressive from transplant. Nine patients received a total of 18 courses of submyechemotherapy. Median WBC at the time of PBSC collection was 14.7 × 10 3 /l (range 1.3-88.2 × 10 3 /l) and loablative chemotherapy with PBSC support for cytoreduction. Patient No. 13 died shortly after PBSC infusion from median ANC was 10.1 × 10 3 /l. The collection time ranged from 1.9 to 6 h per apheresis. The inlet/AC ratios were a rapid progressive leptomeningeal disease and was not evaluable to hematologic recovery. Three patients (Nos 5, between 12:1 and 14:1. The whole blood flow rate ranged from 9 cm 3 /min to 21 cm 3 /min as determined by the 7 and 9) went on to subsequent stem cell transplants. Median days to ANC Ͼ1000/l was 11 days (range 6-17 patient's total blood volume. Total blood processed per leukapheresis ranged from 1100 to 6693 ml, which was equivdays) and platelet count Ͼ100 × 10 3 /l was 17 days (range 11-30 days) from the day of PBSC infusion. Subsequent alent to 2-to 8-fold of blood volume. The average yield per collection was 6.80 Ϯ 1.00 × 10 8 /kg of mononuclear cells chemotherapy was given 15-33 days following PBSC infusion (median 22 days) ( No. 1) did not receive PBSC infusion because tumor cell contamination was found in the PBSC product by immunoobserved. Transient mild hypokalemia (K + Ͻ3.5 mEq/l Ͼ3.0 mEq/l) was noted immediately following apheresis cytochemical studies. and usually self-corrected by the next day. A significant drop of platelets occurred in all patients secondary to trapping of platelets in the PBSC product. The average drop Discussion of platelets after PBSC harvest was 59.8 Ϯ 10.0 × 10 3 /l or 50 Ϯ 3.7%.
In the past, the collection of PBSCs in infants and young children was hampered by technical difficulties such as difNausea and vomiting were common during the PBSC reinfusion and occurred in 75% of patients. Two earlier ficult venous access and lack of cooperation of patients. Young children have a small blood volume to tolerate the patients developed transient hypoxia while receiving a large volume of PBSCs and bone marrow in a short period of redistribution of blood into the extra-corporeal circuit of the apheresis apparatus and they are more susceptible to time. They responded to diuretics and oxygen. Since our procedure has been changed to dividing stem cells into two citrate toxicity. Lasky et al 12 first reported their experience in the collection and use of peripheral blood stem cells in separate infusions if the total stem cell volume was greater than 20 ml/kg, there has been no incidence of hypoxia with three children. They primed the Fenwall CS3000 separator with blood reconstituted with fresh frozen plasma/albumin this new procedure. Transient hemoglobinuria occurred after PBSC infusion in all patients. and packed red blood cells. Heparin was added to ACD-A to increase the whole blood flow rate. ; NA = CD34 determination not done; NE = not evaluable, patient developed gross hematuria and received platelet transfusions to keep platelet count above 100 000/l. employed a pediatric size MedComp hemodialysis catheter
In the initial Lasky et al 12 study, no mobilization was utilized before PBSC collection. The PBSC yield was relafor PBSC collection with success. The MedComp catheter can last for many months after placement and hence is a tively low: 4.8 to 6.4 × 10 8 MNC/kg were collected during six leukapheresis procedures per patient. Mobilization of more convenient device for patients requiring multiple PBSC harvests, high-dose multi-agent chemotherapy and the stem cells with myelosuppressive chemotherapy with or without hematopoietic growth factors greatly facilitates vigorous supportive care.
To improve the yield of collections, we found that PBSC collection and enhances the hematological recovery after high-dose chemotherapy. 6, 7, 18, 19 Takaue et al 16 administering mild sedatives reduced excessive movement in young children and improved the blood flow rate during reported their experience with PBSC collection in 61 children. All patients received myelosuppressive chemotherapy apheresis. The longer collection time per pheresis also improved PBSC yield, decreased the number of procedure prior to apheresis. In 18 children 4 years or under, the total yield was 111 Ϯ 97 × 10 4 CFU-GM/kg from a mean of 3.0 days, and was still well tolerated by our young patients. aphereses, which was significantly better than older children undergoing high-dose therapy. Platelet recovery was correlated with the number of CFU-Meg/kg infused. 20 In dren. Kanold et al 14 found no difference in the number of PBSCs collected or in the hematological reconstitution folour study, the hematological reconstitution was excellent in seven out of eight patients following myeloablative chemolowing PBSC transplant between patients mobilized with G-CSF alone and patients mobilized with chemotherapy therapy. Since the majority of these patients had brain tumors and severe mucositis, we maintained their platelet plus G-CSF or GM-CSF. The median total mononuclear cells collected in their report was 14 × 10 8 /kg (range 6-counts above 50 × 10 3 /l in the early transplant course. In six patients with brain tumors (patient Nos 2, 3, 4, 5, 7, 9), 83 × 10 8 /kg). 14 Deméocq et al 15 reported CFU-GM collected in children receiving hematopoietic growth factor the median days to ANC Ͼ500/l and untransfused platelet Ͼ50 000/l were 10 and 15 days. One heavily pretreated was 7.8-fold higher than in children not receiving growth factors. He also found the cumulative intensity of prior patient had a severe delay in hematologic recovery. His PBSCs were collected 6 months following diagnosis and treatment received is an essential factor in the number of PBSCs collected. Although various assays were employed he had undergone prior abdominal radiation therapy. Single-course, high-dose chemotherapy with autologous stem cell transplantation has been demonstrated to be capexperience compared favorably with other reports in pediatric patients (Table 4) . Sufficient cells for transplant use able of achieving high rates of response in patients in whom conventional chemotherapy has previously failed. These can be collected from a single apheresis. CD34
+ cell assays provide a rapid and reliable assessment of the quantity of responses, however, are frequently of short duration. Curative chemotherapy requires the administration of repeated stem cells collected.
20 WBC counts at the time of apheresis, prior chemotherapy, and radiation therapy affect PBSC courses of effective chemotherapy regimens. A combination of ICE chemotherapy (ifosfamide 1.8 g/m 2 /day × 5 yields. [21] [22] [23] Heavily pretreated patients with limited bone marrow reserve may not have effective mobilization. It is days, etoposide 100 mg/m 2 /day × 5 days, and carboplatin 400 mg/m 2 /day × 2 days) with rhG-CSF support has been important to identify the high-risk patient population who will benefit from high-dose therapy at the time of diagnosis used in children with recurrent or refractory solid tumors. The overall response rate (CR + PR) was 51%. However, and to plan PBSC harvest early in their course of treatment.
After PBSC infusion following high-dose therapy, hemathe treatment was associated with a very high incidence of grade III/IV hematological toxicities. The median tological recovery is correlated with the number of CD34 + cells or CFU-GM/kg. Kawano et al 13 demonstrated that recoveries of ANC to у1000/l and platelets у100 000/l were 16 and 22 days from the completion of chemopatients who received Ͼ1 × 10 5 CFU-GM/kg had an ANC recovery Ͼ0.5 × 10 3 /l between day 6 and 15 (mean therapy. 24 Four patients reported here received a total of seven courses of ICE chemotherapy with PBSC support. 10.5 Ϯ 2.5 days) and the platelet count reached Ͼ50 × 10 3 /l between days 9 and 89 (mean 24 Ϯ 21 days).
Median ANC recovery to у1000/l was 10 days and median platelet recovery to у100 000/l was 14 days. The The ANC recovery in patients receiving Ͻ1 × 10 5 CFU-GM/kg was between day 13 and 39 (22.0 Ϯ 8.4 days); five use of PBSCs may facilitate the hematological recovery and enable repeated cycles of high-dose chemotherapy to be of 10 patients who had received Ͻ1 × 10 5 CFU-GM/kg failed to recover platelets within 8 months. 13 Leibundgut et delivered at short intervals for initial cytoreduction. 25, 26 Several hematopoietic growth factors with thrombopoietic al 20 found a significant correlation between the number of MNC/kg, CFU-GM/kg, CD34 + cells/kg and CD34 + CD33 − activities have been cloned and are currently being investigated in clinical trials. Large clinical trials are needed to cells/kg reinfused and the time to myeloid recovery in chil- 
